Healthcare Sales & Marketing Network News: thrombin receptor antagonist

Searching News Database: thrombin receptor antagonist

HSMN NewsFeed - 12 May 2014
FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 31 Aug 2009
Merck CEO Announces Structure and Global Leadership Team for New Merck
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Mar 2009
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 9 Mar 2009
Merck and Schering-Plough to Merge
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 22 Oct 2007
Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 19 Jul 2007
Schering-Plough Announces Licensing of Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 24 Mar 2007
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Biopharmaceuticals Cardiology

Return to NewsFeed

Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 4 additional stories matching:
thrombin receptor antagonist
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.